Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046207 | 0.89 | SMN1; SMN2 (0.84) | SMN1; SMN2NPC1ALDH1A1RAB9AHPGD | |
| SCHEMBL5445610 | 0.87 | MAPT (0.71) | SMN1; SMN2NPC1ALDH1A1RAB9AHPGD | |
| SCHEMBL3644788 | 0.86 | NPC1 (0.73) | SMN1; SMN2NPC1ALDH1A1RAB9ALMNA | |
| SCHEMBL14095977 | 0.84 | ALDH1A1 (0.58) | SMN1; SMN2NPC1ALDH1A1RAB9AHPGD | |
| SCHEMBL5837764 | 0.84 | ALDH1A1 (0.69) | SMN1; SMN2ALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL14095968 | 0.84 | ALDH1A1 (0.55) | SMN1; SMN2NPC1ALDH1A1RAB9AHPGD | |
| SCHEMBL4357801 | 0.83 | ALDH1A1 (0.62) | SMN1; SMN2NPC1ALDH1A1RAB9AHPGD | |
| SCHEMBL14096632 | 0.83 | NPC1 (0.74) | SMN1; SMN2NPC1ALDH1A1RAB9AHPGD | |
| SCHEMBL5453685 | 0.83 | ALDH1A1 (0.70) | SMN1; SMN2NPC1ALDH1A1RAB9AHPGD | |
| SCHEMBL3049551 | 0.82 | NPC1 (0.78) | SMN1; SMN2NPC1ALDH1A1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20070040151-A1 | Two-component initiator system (amine-free) with very good storage stability and particular suitability for acid systems | HERAEUS KULZER GMBH (DE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | RNASE1, SARS1, EIF2AK2 | SMN1; SMN2 4344/4885NPC1 886/4885ALDH1A1 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.